HOME >> BIOLOGY >> NEWS
New glycan arrays discover autoimmunogenic activities of SARS-CoV: concern over monkey vaccine

Bethesda, MD (July 30, 2004) Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

Using glycan microarrays, the researchers characterized the carbohydrate binding activity of SARS-CoV neutralizing antibodies elicited by an inactivated SARS viral vaccine and found:

1.) An undesired autoantibody reactivity is present in SARS-CoV neutralization antibodies
2.) the autoimmune reactivity is directed toward the complex carbohydrate of an abundant human serum glycoprotein, ASOR (asialo-orosomucoid)
3.) lectin PHA-L is identified as a specific immunologic probe to detect this complex carbohydrate
4.) this lectin stains the SARS-CoV-infected cells specifically and intensively.

The authors said that based on these findings they "have sufficient immunologic evidence that a viral-expressed carbohydrate structure is responsible for the induction of the anti-ASOR autoimmunity in vaccinated animals. These observations raise concerns on human use of the whole virus-based SARS vaccine that is produced by the monkey Vero E6 cell."

They consider that it is too risky to introduce a whole-viral SARS vaccine to human subjects since its immunological property remains largely uncharacterized. They said: "It is necessary to eliminate the undesired autoimmunogenic activity of this preparation of inactivated SARS-CoV. It is possible to identify an alternative cell line or to genetically modify the Vero E6 cell line by altering its glycosylation pathway, thereby producing vaccines with enhanced efficacy without autoimmunogenic activity."

Wang and Lu note that the experimental approaches developed in their research are likely applicable for the immunologic characterization of other viral pathogens.

Research done at Col
'"/>

Contact: Mayer Resnick
mresnick@the-aps.org
301-634-7209
American Physiological Society
30-Jul-2004


Page: 1 2 3 4 5

Related biology news :

1. No longer just for biology, RNA can now be built into 3-D arrays
2. Microarrays, key genome expression trackers, work better when probes are sequence-verified
3. Library on a Slide: Whole genome microarrays for comparative genomics
4. DNA arrays diagnose, predict survival for Sezary syndrome cancer patients
5. Stanfords new antigen microarrays open window to better disease screening
6. Scientists develop protein nanoarrays for biological detection
7. DNA arrays give clues to better vaccines
8. DNA arrays decipher genomes master switches
9. New hydrothermal vents discovered as South Pacific Odyssey research begins
10. Scientists discover potential new way to control drug-resistant bacteria
11. UAF scientists discover new marine habitat in Alaska

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... , ... August 25, 2020 ... ... biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, ... in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution ...
(Date:8/21/2020)... ... 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application ... COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based in Basel, ... license agreements with Housey Pharma’s HMI subsidiary to gain access to its core-enabling ... Research and Development spending in excess of US $10 billion. , Scientists at ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone Partners , ... announced the placement of Julianne Averill , CPA, as Chief Financial Officer ... operations and implementing key business strategies to accelerate Alveo’s growth as the company ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading ... Scientific Advisory Board (SAB) to research the medical potential of terpenes and the potential ... combined with terpenes. The board is focused on expanding the recently launched line of ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 12, 2020 , ... ... Group, Inc. (EMMA International), a global leader in FDA compliance consulting has ... the nation’s fastest-growing private companies. The list represents a unique look at the ...
Breaking Biology Technology:
Cached News: